Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post

Caplin Point Laboratories Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹1,471.15Fairly Valued by 6.30%vs CMP ₹1,570.00

P/E (19.4) × ROE (22.7%) × BV (₹416.00) × DY (0.38%)

₹1,014.05Overvalued by 35.41%vs CMP ₹1,570.00
MoS: -54.8% (Negative)Confidence: 58/100 (Moderate)Models: 2 Fair, 7 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹1,696.7822%Fair (+8.1%)
Graham NumberEarnings₹869.3316%Over (-44.6%)
Earnings PowerEarnings₹503.9713%Over (-67.9%)
DCFCash Flow₹1,678.3311%Fair (+6.9%)
Net Asset ValueAssets₹415.557%Over (-73.5%)
EV/EBITDAEnterprise₹753.899%Over (-52%)
Earnings YieldEarnings₹807.407%Over (-48.6%)
ROCE CapitalReturns₹895.559%Over (-43%)
Revenue MultipleRevenue₹254.805%Over (-83.8%)
Consensus (9 models)₹1,014.05100%Overvalued
Key Drivers: Wide model spread (₹255–₹1,697) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 15.3%

*Investments are subject to market risks

Analyst Summary

Caplin Point Laboratories Ltd operates in the Pharmaceuticals segment, NSE: CAPLIPOINT | BSE: 524742, current market price is ₹1,570.00, market cap is 11,935 Cr.. At a glance, stock P/E is 19.4, ROE is 22.7 %, ROCE is 25.8 %, book value is 416, dividend yield is 0.38 %. The latest intrinsic value estimate is ₹1,014.05, around 35.4% below the current price, so expectations may already be running ahead of this modelled fair value. On operating trend, latest reported sales are about ₹1,937 Cr versus the prior period change of 14.3%, while latest net profit is about ₹541 Cr with a prior-period change of 17.4%. The 52-week range shown on this page is 2,397/1,500, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisCaplin Point Laboratories Ltd. is a Public Limited Listed company incorporated on 16/04/1990 and has its registered office in the State of Tamil Nadu, India. Company's Corporate Identification Number(…

This summary is generated from the stock page data available for Caplin Point Laboratories Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

73
Caplin Point Laboratories Ltd scores 73/100 (Strong)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health88/100 · Strong
ROCE 25.8% ExcellentROE 22.7% ExcellentD/E 0.01 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money60/100 · Moderate
FII holding up 0.85% (6mo) Slight increasePromoter holding at 70.6% Stable
Earnings Quality55/100 · Moderate
OPM expanding (31% → 34%) ImprovingWorking capital: 233 days Capital intensive
Quarterly Momentum68/100 · Strong
Revenue (4Q): +11% YoY GrowingProfit (4Q): +20% YoY Positive
Industry Rank90/100 · Strong
P/E 19.4 vs industry 53.8 Cheaper than peersROCE 25.8% vs industry 16.4% Above peersROE 22.7% vs industry 15.2% Above peers3Y sales CAGR: 15% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 2:44 am

Market Cap 11,935 Cr.
Current Price 1,570
Intrinsic Value₹1,014.05
High / Low 2,397/1,500
Stock P/E19.4
Book Value 416
Dividend Yield0.38 %
ROCE25.8 %
ROE22.7 %
Face Value 2.00
PEG Ratio1.26

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Caplin Point Laboratories Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Caplin Point Laboratories Ltd 11,935 Cr. 1,570 2,397/1,50019.4 4160.38 %25.8 %22.7 % 2.00
Cohance Lifesciences Ltd 11,934 Cr. 312 1,250/26739.7 99.00.00 %14.9 %12.7 % 1.00
Jubilant Pharmova Ltd 13,008 Cr. 817 1,250/78428.2 4140.61 %9.54 %9.55 % 1.00
Concord Biotech Ltd 10,671 Cr. 1,020 2,150/99033.6 1741.05 %28.4 %21.4 % 1.00
Alembic Pharmaceuticals Ltd 13,308 Cr. 677 1,108/63520.1 2711.62 %13.0 %11.4 % 2.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Caplin Point Laboratories Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 372389395410436453459483493502510534543
Expenses 263265269273293308307318331334332345353
Operating Profit 109124127137142145152165162168178189190
OPM % 29%32%32%34%33%32%33%34%33%33%35%35%35%
Other Income 14111221171719213126233034
Interest 0000000000000
Depreciation 11111112141616171617161819
Profit before tax 112124127146145146154168177177184201204
Tax % 13%18%18%20%18%17%19%22%21%18%18%20%19%
Net Profit 97101104116120121125131140145151160166
EPS in Rs 12.8413.4513.6215.1315.4316.0116.3117.2118.2818.7620.1020.3221.56

Last Updated: February 6, 2026, 9:46 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 25, 2026, 5:30 am

MetricJun 2014Jun 2015Mar 2016n n n 9mMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 1732522394025406498631,0611,2691,4671,6941,9372,089
Expenses 1371921752763454176037328741,0251,1421,2871,365
Operating Profit 366064125195232260329395442552651725
OPM % 21%24%27%31%36%36%30%31%31%30%33%34%35%
Other Income 434101319412338556692113
Interest 1101110211111
Depreciation 48713192332374745536671
Profit before tax 365360121188227269314386451564677766
Tax % 27%23%24%21%23%22%20%20%20%16%18%20%
Net Profit 26414696145177215251308377461541622
EPS in Rs 3.425.436.0512.6519.1523.3528.4232.0339.5649.5760.1970.5680.74
Dividend Payout % 23%18%20%12%10%9%9%9%10%9%8%8%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)51.04%22.07%21.47%16.74%22.71%22.40%22.28%17.35%
Change in YoY Net Profit Growth (%)0.00%-28.97%-0.60%-4.72%5.96%-0.31%-0.12%-4.93%

Caplin Point Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:27%
5 Years:18%
3 Years:15%
TTM:13%
Compounded Profit Growth
10 Years:35%
5 Years:20%
3 Years:21%
TTM:18%
Stock Price CAGR
10 Years:22%
5 Years:32%
3 Years:40%
1 Year:8%
Return on Equity
10 Years:27%
5 Years:24%
3 Years:23%
Last Year:22%

Last Updated: September 5, 2025, 1:35 am

Balance Sheet

Last Updated: December 4, 2025, 1:05 am

MonthJun 2014Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 15151515151515151515151515
Reserves 47781132103495828589541,2521,6492,0842,6193,144
Borrowings 32211361132352192222192225
Other Liabilities 115134137133136109139159250305380352339
Total Liabilities 1802292673585007431,1261,3641,7362,1912,6983,2083,504
Fixed Assets 102113144152169227272305287280453546555
CWIP 2531031510201418221117144177
Investments 000174770611189281376590636
Other Assets 52851221862694367721,0331,3431,4101,7531,9282,135
Total Assets 1802292673585007431,1261,3641,7362,1912,6983,2083,504

Reserves and Borrowings Chart

Cash Flow

MonthJun 2014Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 60504268668345269337271318432
Cash from Investing Activity + -44-23-6-36-69-100-54-30-377-216-319-333
Cash from Financing Activity + -6-9-14-7-129080-24-41-28-38-38
Net Cash Flow 10192325-147370215-8127-3961
Free Cash Flow 132434431818-3219524678173241
CFO/OP 186%103%92%73%53%54%38%102%106%81%77%86%

Free Cash Flow

MonthJun 2014Jun 2015Mar 2016n n n 9mMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow33.0058.0064.00124.00194.00196.00147.0094.00176.00220.00333.00429.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthJun 2014Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 081230859097969198117119
Inventory Days 353757444447210139149159183159
Days Payable 11211216815514476576810284106103
Cash Conversion Cycle -77-67-99-81-1661251166138173194175
Working Capital Days -181-128-114-2947104167145165144166233
ROCE %64%68%62%68%63%45%33%28%28%26%26%26%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 70.66%70.63%70.62%70.62%70.62%70.56%70.56%70.56%70.56%70.56%70.57%70.57%
FIIs 2.36%2.68%3.09%2.84%3.33%3.38%3.71%4.86%5.73%6.16%6.51%6.58%
DIIs 0.64%0.27%0.21%0.43%1.08%1.49%1.83%2.11%2.00%2.22%2.10%2.05%
Public 26.33%26.44%26.08%26.11%24.95%24.59%23.93%22.48%21.72%21.06%20.82%20.81%
No. of Shareholders 82,14678,95678,06879,43881,40980,41196,12392,70296,38794,16993,75393,705

Shareholding Pattern Chart

No. of Shareholders

Caplin Point Laboratories Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
UTI Small Cap Fund 376,835 1.47 66.85363,1492026-01-25 05:11:423.77%
UTI Large & Mid Cap Fund 301,541 0.95 53.49300,7012026-02-22 05:22:410.28%
UTI Aggressive Hybrid Fund 278,474 0.74 49.4277,3532026-02-22 05:22:410.4%
UTI Healthcare Fund 145,000 2.44 25.72130,8372026-01-25 05:11:4210.82%
UTI Retirement Fund 108,425 0.41 19.23107,5852026-02-22 05:22:410.78%
ITI Pharma and Healthcare Fund 10,449 0.88 1.859,8672025-12-15 04:31:045.9%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 2.002.002.002.002.00
Basic EPS (Rs.) 70.5760.1949.6239.6132.03
Diluted EPS (Rs.) 70.2559.9049.1839.2631.71
Cash EPS (Rs.) 79.8867.7955.6046.8838.13
Book Value[Excl.RevalReserv]/Share (Rs.) 365.25299.18241.46189.35159.08
Book Value[Incl.RevalReserv]/Share (Rs.) 365.25299.18241.46189.35159.08
Revenue From Operations / Share (Rs.) 254.93223.05193.25167.47140.30
PBDIT / Share (Rs.) 97.8181.4265.4957.1846.56
PBIT / Share (Rs.) 89.1374.3859.5650.9941.67
PBT / Share (Rs.) 89.0574.3259.4750.9041.46
Net Profit / Share (Rs.) 71.2060.7549.6740.6933.24
NP After MI And SOA / Share (Rs.) 70.5760.1849.5739.5632.03
PBDIT Margin (%) 38.3636.5033.8834.1433.18
PBIT Margin (%) 34.9633.3430.8230.4429.70
PBT Margin (%) 34.9333.3130.7730.3929.55
Net Profit Margin (%) 27.9227.2325.7024.2923.69
NP After MI And SOA Margin (%) 27.6826.9825.6523.6222.82
Return on Networth / Equity (%) 19.3220.3920.8321.2720.43
Return on Capital Employeed (%) 23.3423.8623.5025.2825.82
Return On Assets (%) 16.7116.9417.1617.2617.76
Total Debt / Equity (X) 0.000.000.000.000.01
Asset Turnover Ratio (%) 0.650.690.740.430.48
Current Ratio (X) 6.975.715.806.257.25
Quick Ratio (X) 5.884.624.725.156.00
Inventory Turnover Ratio (X) 5.540.730.801.410.85
Dividend Payout Ratio (NP) (%) 0.007.478.050.001.24
Dividend Payout Ratio (CP) (%) 0.006.697.190.001.08
Earning Retention Ratio (%) 0.0092.5391.950.0098.76
Cash Earning Retention Ratio (%) 0.0093.3192.810.0098.92
Interest Coverage Ratio (X) 1218.62792.79637.23619.17221.55
Interest Coverage Ratio (Post Tax) (X) 888.05592.22484.22441.64159.17
Enterprise Value (Cr.) 14664.809483.554065.674717.102632.14
EV / Net Operating Revenue (X) 7.575.602.773.722.48
EV / EBITDA (X) 19.7315.348.1810.887.47
MarketCap / Net Operating Revenue (X) 7.865.913.094.062.88
Retention Ratios (%) 0.0092.5291.940.0098.75
Price / BV (X) 5.484.462.513.662.58
Price / Net Operating Revenue (X) 7.865.913.094.062.88
EarningsYield 0.030.040.080.050.07

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Caplin Point Laboratories Ltd. is a Public Limited Listed company incorporated on 16/04/1990 and has its registered office in the State of Tamil Nadu, India. Company's Corporate Identification Number(CIN) is L24231TN1990PLC019053 and registration number is 019053. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 752.41 Cr. and Equity Capital is Rs. 15.20 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Pharmaceuticals3rd Floor, Ashvich Towers, No.3, Developed Plots Industrial Chennai (Madras) Tamil Nadu 600096Contact not found
Management
NamePosition Held
Mr. C C PaarthipanChairman
Dr. Sridhar GanesanManaging Director
Dr. R NagendranIndependent Director
Mr. S DeenadayalanIndependent Director
Dr. C K GariyaliIndependent Director
Mr. R VijayaraghavanIndependent Director

FAQ

What is the intrinsic value of Caplin Point Laboratories Ltd and is it undervalued?

As of 21 April 2026, Caplin Point Laboratories Ltd's intrinsic value is ₹1014.05, which is 35.41% lower than the current market price of ₹1,570.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (22.7 %), book value (₹416), dividend yield (0.38 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Caplin Point Laboratories Ltd?

Caplin Point Laboratories Ltd is trading at ₹1,570.00 as of 21 April 2026, with a FY2026-2027 high of ₹2,397 and low of ₹1,500. The stock is currently near its 52-week low. Market cap stands at ₹11,935 Cr..

How does Caplin Point Laboratories Ltd's P/E ratio compare to its industry?

Caplin Point Laboratories Ltd has a P/E ratio of 19.4, which is below the industry average of 53.84. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Caplin Point Laboratories Ltd financially healthy?

Key indicators for Caplin Point Laboratories Ltd: ROCE of 25.8 % indicates efficient capital utilization; ROE of 22.7 % shows strong shareholder returns. Dividend yield is 0.38 %.

Is Caplin Point Laboratories Ltd profitable and how is the profit trend?

Caplin Point Laboratories Ltd reported a net profit of ₹541 Cr in Mar 2025 on revenue of ₹1,937 Cr. Compared to ₹308 Cr in Mar 2022, the net profit shows an improving trend.

Does Caplin Point Laboratories Ltd pay dividends?

Caplin Point Laboratories Ltd has a dividend yield of 0.38 % at the current price of ₹1,570.00. The company pays dividends, though the yield is modest.

Last Updated: April 2, 2026, 2:44 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 524742 | NSE: CAPLIPOINT
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Caplin Point Laboratories Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports